BioSpace News Archive

Drug Development

TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline

Results from a prespecified exploratory analysis of the FLAURA2 Phase III trial showed AstraZeneca.

October 21, 2023
·
12 min read
Drug Development

Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

ORIC Pharmaceuticals, Inc. announced initial data from the ongoing ORIC-114 Phase 1 dose escalation trial for patients with EGFR or HER2 exon 20 mutated non-small cell lung cancer at the European Society of Medical Oncology Congress 2023.

October 21, 2023
·
10 min read
Drug Development

Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select FGFR Alterations Treated with BALVERSA® (erdafitinib) Versus Chemotherapy

The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the Phase 2 randomized, open-label THOR-2 study evaluating BALVERSA® versus investigator choice of intravesical chemotherapy in patients with high-risk non-muscle-invasive bladder cancer and select fibroblast growth factor receptor alterations which recurred after Bacillus Calmette-Guérin therapy.

October 21, 2023
·
16 min read
Biotech Beach

Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis’ MRD Technology

Personalis, Inc., a leader in precision oncology, announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking a substantial advancement in lung cancer circulating tumor DNA detection and management.

October 21, 2023
·
7 min read
Drug Development

F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TIMM) 2023 Demonstrating Positive Therapeutic Responses in Patients with Invasive Fungal Infections Treated with Oral Olorofim

F2G Ltd. and Shionogi & Co., Ltd., announced full results from the pivotal Phase 2b open-label study of olorofim in patients with proven invasive fungal infections or probable pulmonary invasive aspergillosis and limited or no treatment options.

October 21, 2023
·
10 min read
Pharm Country

Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

Regeneron Pharmaceuticals, Inc. announced the first presentation of key secondary endpoints for an investigational regimen of PD-1 inhibitor Libtayo® as a neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma.

October 21, 2023
·
19 min read